Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Affiliations

¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hclee@mdanderson.org.
² Center for Multiple Myeloma, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
⁴ Clinical Pharmacology Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA.
⁵ Bioanalytical Sciences, Amgen Inc., Thousand Oaks, CA, USA.
⁶ Clinical Biomarkers & Diagnostics, Amgen Inc., South San Francisco, CA, USA.
⁷ Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
⁸ Clinical Development, Amgen Inc., Thousand Oaks, CA, USA.
⁹ Translational Medicine, Amgen Inc., South San Francisco, CA, USA.
¹⁰ Malignant Haematology & Stem Cell Transplantation Service, The Alfred Hospital, Monash University, Melbourne, VIC, Australia.

Clinical Trial

Hans C Lee et al. Leukemia. 2021 Jan.

. 2021 Jan;35(1):255-258.

doi: 10.1038/s41375-020-0834-9. Epub 2020 Apr 21.

¹ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hclee@mdanderson.org.
² Center for Multiple Myeloma, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
⁴ Clinical Pharmacology Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA.
⁵ Bioanalytical Sciences, Amgen Inc., Thousand Oaks, CA, USA.
⁶ Clinical Biomarkers & Diagnostics, Amgen Inc., South San Francisco, CA, USA.
⁷ Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA.
⁸ Clinical Development, Amgen Inc., Thousand Oaks, CA, USA.
⁹ Translational Medicine, Amgen Inc., South San Francisco, CA, USA.
¹⁰ Malignant Haematology & Stem Cell Transplantation Service, The Alfred Hospital, Monash University, Melbourne, VIC, Australia.

No abstract available

References

1. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8. - DOI
1. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75. - DOI
1. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60. - DOI
1. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–94. - DOI
1. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007;179:7276–86. - DOI